OnKure Therapeutics, Inc. (OKUR) 股票分析

公司概述

OnKure Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. The company functions within the Healthcare sector, specifically the Biotechnology industry, where its primary focus is on advancing therapeutic candidates such as OKI-219, a selective inhibitor of phosphoinositide 3-kinase. As of the latest reporting period, OnKure Therapeutics maintains a market capitalization of $54.56M and employs a workforce of 45 individuals to support its research and development initiatives. The market capitalization figure of $54.56M indicates that the company is a small-cap entity with a relatively modest enterprise valuation, while the absence of reported annual revenue figures suggests the company is still in a pre-revenue or early-stage commercialization phase typical for clinical-stage biotechnology firms.

财务健康

The financial statements reveal that OnKure Therapeutics reported a Net Income of $-59,517,000 and an EBITDA of $-62,503,000 over the trailing twelve-month period, with Revenue figures listed as N/A. The substantial gap between the reported Net Income of $-59,517,000 and the EBITDA of $-62,503,000, alongside the lack of revenue data, highlights a cost structure heavily driven by research and development expenses rather than operational overhead associated with sales. The company generated Free Cash Flow of $-31,100,750, indicating a significant cash outflow that reflects the capital-intensive nature of clinical-stage development where funds are being consumed to advance product candidates. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which is indicative of a company that has not yet generated sufficient revenue to establish positive operating leverage or profitability. Regarding liquidity and leverage, the company holds $59.05M in Cash against $549,000 in Debt, resulting in a Debt to Equity ratio of 0.98 and a Current Ratio of 10.28. The Current Ratio of 10.28 suggests an extremely strong short-term liquidity position with ample current assets relative to current liabilities, although the massive cash balance is primarily reserved for funding ongoing clinical trials rather than servicing debt. The Return on Equity stands at -74.4% and the Return on Assets at -44.5%, revealing that management is currently utilizing the company's capital base to generate losses as they invest resources into future drug development rather than returning value to shareholders through earnings.

估值评估

OnKure Therapeutics presents a valuation profile characterized by negative earnings multiples, with a Trailing P/E Ratio (TTM) listed as N/A and a Forward P/E of -1.40. The distinction between a non-existent trailing P/E and a negative forward P/E implies that the market is pricing the stock based on potential future earnings expectations that are currently projected to remain negative or are not yet realized. The Price to Book ratio is 0.97, indicating that the company's market capitalization is trading slightly below its book value, which often suggests that the market has assigned a lower premium to the company's assets compared to established pharmaceutical peers. Alternative valuation metrics such as Price to Sales, which is N/A, and an EV/EBITDA of 0.06 provide limited traditional valuation context due to the company's lack of revenue and negative earnings. The stock's price range over the last year fluctuated between a 52-Week Low of $1.70 and a 52-Week High of $5.10, with the current trading price sitting within this historical range. The Beta value is listed as N/A, meaning there is no available data to quantify the stock's volatility relative to the broader market, though the small market cap of $54.56M generally implies higher sensitivity to market movements than large-cap biotechnology firms.

Growth & Income

Growth metrics for OnKure Therapeutics are currently undefined, with Revenue Growth (YoY) and Earnings Growth (YoY) both reported as N/A due to the company's status as a clinical-stage entity without established recurring revenue streams. Consequently, it is not possible to determine if earnings are growing faster or slower than revenue, as neither metric exists in a conventional growth framework for this stage of development. As a non-dividend payer, the company reports a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning it does not distribute cash to shareholders and instead reinvests all available resources, including its $59.05M cash reserve, into research and development activities. The overall growth and income profile for OnKure Therapeutics is defined by a total reliance on future commercial success of its pipeline to generate revenue, rather than current income generation or dividend distributions to investors.